Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for KalVista Pharmaceuticals (KALV) over the last 6 years, with Q1 2020 value amounting to $1.3 million.

  • KalVista Pharmaceuticals' Current Deferred Revenue fell 8909.11% to $1.3 million in Q1 2020 from the same period last year, while for Jan 2020 it was $1.3 million, marking a year-over-year decrease of 8909.11%. This contributed to the annual value of $9.5 million for FY2019, which is 4833.56% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $1.3 million for Q1 2020, which was down 8909.11% from $2.6 million recorded in Q4 2019.
  • KalVista Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $20.0 million during Q1 2018, with a 5-year trough of $29000.0 in Q1 2016.
  • In the last 4 years, KalVista Pharmaceuticals' Current Deferred Revenue had a median value of $10.9 million in 2019 and averaged $10.2 million.
  • In the last 5 years, KalVista Pharmaceuticals' Current Deferred Revenue crashed by 3843.27% in 2019 and then tumbled by 8909.11% in 2020.
  • Quarter analysis of 4 years shows KalVista Pharmaceuticals' Current Deferred Revenue stood at $29000.0 in 2016, then skyrocketed by 50827.59% to $14.8 million in 2018, then tumbled by 82.39% to $2.6 million in 2019, then crashed by 48.37% to $1.3 million in 2020.
  • Its Current Deferred Revenue was $1.3 million in Q1 2020, compared to $2.6 million in Q4 2019 and $6.0 million in Q3 2019.